I am the Director of Wolfson Institute of Preventive Medicine and also Head of Centre for Cancer Prevention. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.
My lab measures the patterns of clonal evolution that define carcinogenesis and develops novel mathematical tools for analysis and prediction. By characterising tumour evolution, we aim to find better ways to determine prognosis and more effective ways to treat cancers.
Cancers are composed of both tumour and stromal compartments. We are interested in understanding the molecular basis of how the tumour stroma contributes to tumour growth, therapy resistance and spread, in various solid tumours including lung cancers, pancreatic cancer and melanoma.
My clinical research interests include tissue banking, clinical trials, innovative surgical techniques, epidemiology, meta-analysis and patient care pathways. My translational research interests include pancreatic cancer stroma and tumour-stroma cross-talk including cell signalling, adhesion, metastasis and invasion.
My main research focus is based on the development of population based approaches to genetic testing for risk stratification, cancer prevention and using targeted surgical approaches for cancer prevention in gynaecological cancers.
My research interests lie in the area of translational bioinformatics. Current research projects are focused in high-throughput data analysis, integration with clinical data, databases and software development, particularly for pancreatic cancer and breast cancer.
My research group uses unique proteomics and computational approaches to understand how cell signalling pathways driven by the activity of protein kinases contribute to the development of cancer. Increasing this knowledge will be invaluable in advancing personalised cancer therapies.
My group works on developing novel approaches to improve efficacy and safety of allogeneic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers. We focus on T-cell alloreactivity in the context of stem cell transplantation and immunotherapy.
My group focuses on immunological approaches to the treatment of haematological cancers. My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
I am interested in studying the effects of the inflammatory microenvironment on disease progression and resistance to treatment in haematological malignancies with emphasis on survival and mechanisms of treatment resistance in chronic lymphocytic leukaemia and B cell lymphoma.
Our research aims to understand the biology of leukaemia stem cells and identify tricks they use to escape treatments. My group employs multidisciplinary approaches to understand how HSCs chose to self-renew or differentiate and how these cell fate decisions are affected under pathological conditions to generate leukaemic stem cells.
My research interests are to apply tissue-engineered technologies to study the role of the microenvironment in modulating cancer progression and therapy response. I develop 3D models that mimic the human disease and use this to develop novel therapies.
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Our research is based on exploiting DNA repair defects in cancer for the identification of new personalised therapies. We use compound and siRNA screening to identify new therapeutics for tumours based on their specific DNA repair status.
I am a leading expert in establishing higher education degrees for acquiring operative surgical skills by simulation. I pioneered the Masters course in Surgical Skills and Sciences at Barts Cancer Institute and have set up a “Virtual Reality Surgical Simulation Centre” for training surgeons.
My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, transcriptomic changes during PCa treatment, and liquid biopsy molecular biomarkers of treatment outcomes. My clinical research investigates patterns of treatment outcomes for PCa patients.
My main interests are in radiopharmaceutical development and the use of pre-clinical molecular imaging in drug development, especially biopharmaceuticals. The lab has a long-standing interest in imaging CCK-2 and GRP receptors which are overexpressed in a number of tumour types.
My research focuses on the fundamental aspects of leukaemia initiating cell (LIC) biology in adult acute lymphoblastic leukaemia, with the aim of gaining fundamental insight into the underlying biology of LICs to reveal dependencies that are tractable targets for therapy.
My research interests include clonal evolution in colorectal adenomas and inflammation-associated cancer, the nature of Barrett’s glands, and the design of methods to explore neutral drift in stem cell divisions in normal human tissues.
My research is focused on describing the mechanisms underlying Lamin B1 nuclear disassembly in B-cell normal development and how a dis-regulated Lamin B1 removal pathway could lead to several haematological malignancies within the germinal centre in secondary lymph organs.
We are updating the bioinformatics data management system, expanding the analytical modules and functionalities, developing purpose-built graphical pug-ins and designing the bioinformatics infrastructure to allow the querying and analysis of data returned from projects using BCNTB tissues.
I am a Bioinformatician working on the development of pipelines for NGS data analysis, including mutational calling, Single-Cell RNA-seq, ChIP peak calling and methylation, variant annotation and prioritisation, as well as multi-layer data integration strategy and tools.
My research is focussed on the disturbed epigenomic landscape within pancreatic tumours.
In particular, I investigate the bi-directional epigenetic reprogramming between the tumour microenvironment and pancreatic cancer stem cells that leads to cooperative tumour outgrowth.
The Receptor Tyrosine Kinase c-Met continues its signalling life cycle post-endocytosis. Our group has shown that internalised c-Met traffics through endomembranes positive for LC3B and Beclin1. Furthermore, c-Met sustains signalling from Autophagy Related Endomembranes, ARE. We hypothesised therefore that the AREs supporting c-Met trafficking and signalling belong to a novel non-canonical pathway .
High-grade serous ovarian cancer (HGSOC) represents the major subtype of ovarian cancer and displays high levels of chromosomal instability.
We are collaborating with the Balkwill and Lockley laboratories to investigate mechanisms driving chromosomal instability in gynaecological cancers.
I apply mathematical and computational approaches to understanding cancer evolution. A lot of my work is inspired by population genetics and evolutionary biology and I have been developing ways to adapt methods and theories from these fields to the study of cancer as an evolutionary system.